Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optive and Systane are two distinct brands of over-the-counter (OTC) lubricant eye drops, also known as artificial tears, used for the symptomatic relief of dry eye syndrome (keratoconjunctivitis sicca). Optive, developed by Allergan (now part of AbbVie), is a dual-action formula containing carboxymethylcellulose sodium (CMC) and glycerin; it acts as a lubricant and osmoprotectant to stabilize the tear film and protect the ocular surface. Systane, developed by Alcon, is typically formulated with polyethylene glycol 400 and propylene glycol, utilizing a unique hydroxypropyl guar (HP-guar) gelling system that forms a protective matrix on the eye surface upon contact with tears. These products are frequently compared in clinical settings, such as Phase 4 trials sponsored by Innovative Medical, to evaluate subjective patient preferences, duration of action, and frequency of use in mild to moderate dry eye cases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Optive, Systane.